DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages



Author(s): Nikhil Dwivedi, Medical Student, Bond University; Dr Ramez Barsoum, Dermatology Registrar, Australia. August 2022


What is lobomycosis?

Lobomycosis is a rare, chronic, fungal infection of the skin and subcutaneous tissue.

Lobomycosis, also referred to as keloidal blastomycosis, Jorge Lobo disease, Lobo disease, or lacaziosis, is a deep mycosis of the skin. It is characterised by keloidal skin lesions that often remain well-localised.


Click here for all images

Who gets lobomycosis?

Lobomycosis primarily occurs in the tropical climates of Central and South America, and most commonly presents in rural communities in countries such as Brazil, Venezuela, Colombia, and Guyana.

What causes lobomycosis?

Lobomycosis is caused by Lacazia loboi. The organism is an uncultivable dimorphic onygenales fungus that is found in water, soil, and vegetation. It is thought that traumatic implantation of the fungus into the dermis is the most likely mode of transmission. Lobomycosis does not appear to spread through human-to-human transmission. 

What are the clinical features of lobomycosis? 

Often after several months, an indurated painless papule develops in the superficial or deep dermis. Over subsequent months to years, the area of involvement expands contiguously, with the development of single or multiple polymorphic plaques or nodules that resemble keloid scars. These cutaneous lesions often have a smooth, shiny and intact surface and their colour can vary from skin colour to darker red-brown. Telangiectasia may also be present.

Older and more chronic lesions can present as crusted fungating plaques. 

These lesions may be found anywhere, but are usually found on exposed parts (ie, arms, legs, pinna, and face). Patients do not typically experience pruritus or dysesthesia, however, these may be present in extensive cases. 

What are the complications of lobomycosis?

  • Disfigurement and deformation causing functional and aesthetic concerns
  • Ulceration
  • Superinfection of ulcerated lesions
  • Malignant transformation — squamous cell carcinoma has been reported in chronic lesions.

How is lobomycosis diagnosed?

The diagnosis is made on clinical suspicion and direct microscopic examination. Skin biopsy is the gold standard for diagnostic confirmation; visualisation of the fungal forms are best obtained with the use of silver or periodic acid-Schiff (PAS) stain.

Lobomycosis pathology

Click here for all images

What is the differential diagnosis for lobomycosis?

What is the treatment for lobomycosis?

Specific measures

What is the outcome of lobomycosis?

Lobomycosis has a slow and progressive involvement of the skin and subcutaneous tissue. Extensive or chronic disease can lead to tissue destruction and disfigurement. It is very rare for the disease to resolve spontaneously. There have been some cases of patients developing squamous cell carcinoma in chronic lesions.

Click here for images



  • Elsayed S, Kuhn SM, Barber D, Church DL, Adams S, Kasper R. Human case of lobomycosis. Emerg Infect Dis. 2004;10(4):715–8. doi:10.3201/eid1004.030416. Journal
  • Francesconi VA, Klein AP, Santos AP, Ramasawmy R, Francesconi F. Lobomycosis: epidemiology, clinical presentation, and management options. Ther Clin Risk Manag. 2014;10:851–60. Published 2014 Oct 9. doi:10.2147/TCRM.S46251. PubMed Central
  • Gonçalves FG, Rosa PS, Belone AFF, et al. Lobomycosis Epidemiology and Management: The Quest for a Cure for the Most Neglected of Neglected Tropical Diseases. J Fungi (Basel). 2022;8(5):494. Published 2022 May 10. doi:10.3390/jof8050494 Journal
  • Talhari S, Talhari C. Lobomycosis. Clin Dermatol. 2012;30(4):420–4. doi:10.1016/j.clindermatol.2011.09.014. Journal

On DermNet

Other websites

Books about skin diseases


Related information

Sign up to the newsletter